zecs, I think the most important part of that paragraph came after those words you have quoted:
This use has included in men whose cancer has failed to respond to the 177lutetium-PSMA alone, with Veyonda being used to overcome resistance to 177lutetium-PSMA, a potential major market opportunity
A cynic might say that mOS of 19.7 months in 56 patients is too small a sample to be reliable, but it is now clear that the combination of NOX66 plus Lu-PSMA is able to overcome resistance to Lu-PSMA alone. The evidence is incontrovertible: NOX66+Lu-PSMA is vastly superior to Lu-PSMA alone.
zecs, I think the most important part of that paragraph came...
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.5¢ |
Change
0.010(9.52%) |
Mkt cap ! $33.60M | |||
| Open | High | Low | Value | Volume |
| 12.5¢ | 14.0¢ | 11.0¢ | $559.0K | 4.481M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6612 | 11.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.0¢ | 99714 | 1 |
View Market Depth
| Last trade - 16.10pm 03/09/2024 (20 minute delay) ? |
| NOX (ASX) Chart |